Literature DB >> 17919485

Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome.

Jukka-Pekka Mecklin1, Markku Aarnio, Esa Läärä, Matti V Kairaluoma, Kirsi Pylvänäinen, Päivi Peltomäki, Lauri A Aaltonen, Heikki J Järvinen.   

Abstract

BACKGROUND & AIMS: Mutation carriers in Lynch syndrome families have a high risk for developing colorectal cancer during their lifetime. This study was designed to assess the cumulative risk for the development of colorectal adenoma or carcinoma in prospective colonoscopic surveillance.
METHODS: Data from the Finnish Hereditary Colorectal Cancer Registry electronic database on 420 Lynch syndrome mutation carriers without previous colorectal tumors were reviewed. Between March 1982 and May 2005 the mutation carriers underwent a total of 1252 colonoscopies. The total follow-up time was 3150 years (mean, 6.7 y/patient).
RESULTS: The cumulative risk of adenoma by age 60 was estimated as 68% (95% confidence interval [CI], 50%-80%) in men and 48% (95% CI, 29%-62%) in women. The estimated cumulative risk up to age 60 years for the development of cancer found as a result of surveillance at an interval of 2-3 years was 35% (95% CI, 16%-49%) in men and 22% (95% CI, 7%-34%) in women. Half of the adenomas were located proximal to the splenic flexure. Extracolonic cancer was diagnosed in 73 patients (18%).
CONCLUSIONS: Adenoma would appear to be the most important lesion preceding cancer formation in Lynch syndrome and removal of adenomas decreases the risk for colorectal cancer (CRC). The Finnish surveillance protocol of colonoscopies at 2- to 3-year intervals facilitates patient adherence but includes an essential risk for CRC up to 60 years of age, but without CRC-related mortality when the surveillance instructions are followed.

Entities:  

Mesh:

Year:  2007        PMID: 17919485     DOI: 10.1053/j.gastro.2007.08.019

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

1.  Rapid development of colorectal neoplasia in patients with Lynch syndrome.

Authors:  Daniel L Edelstein; Jennifer Axilbund; Melanie Baxter; Linda M Hylind; Katharine Romans; Constance A Griffin; Marcia Cruz-Correa; Francis M Giardiello
Journal:  Clin Gastroenterol Hepatol       Date:  2010-11-09       Impact factor: 11.382

2.  Controversies in the surgery of patients with familial adenomatous polyposis and Lynch syndrome.

Authors:  James M Church
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

Review 3.  Prophylactic surgery in Lynch syndrome.

Authors:  V Celentano; G Luglio; G Antonelli; R Tarquini; L Bucci
Journal:  Tech Coloproctol       Date:  2011-02-02       Impact factor: 3.781

Review 4.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 5.  Familial colorectal cancer, beyond Lynch syndrome.

Authors:  Elena M Stoffel; Fay Kastrinos
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-17       Impact factor: 11.382

6.  Worldwide Practice Patterns in Lynch Syndrome Diagnosis and Management, Based on Data From the International Mismatch Repair Consortium.

Authors:  Jennifer Y Pan; Robert W Haile; Allyson Templeton; Finlay Macrae; FeiFei Qin; Vandana Sundaram; Uri Ladabaum
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-24       Impact factor: 11.382

7.  Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome.

Authors:  Elena M Stoffel; Rowena C Mercado; Wendy Kohlmann; Beth Ford; Shilpa Grover; Peggy Conrad; Amie Blanco; Kristen M Shannon; Mark Powell; Daniel C Chung; Jonathan Terdiman; Stephen B Gruber; Sapna Syngal
Journal:  Am J Gastroenterol       Date:  2010-03-30       Impact factor: 10.864

Review 8.  Colorectal surveillance in Lynch syndrome families.

Authors:  Wouter H de Vos tot Nederveen Cappel; Heikki J Järvinen; Patrick M Lynch; Christoph Engel; Jukka-Pekka Mecklin; Hans F A Vasen
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

9.  Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing.

Authors:  Jennifer M Matro; Karen J Ruth; Yu-Ning Wong; Katen C McCully; Christina M Rybak; Neal J Meropol; Michael J Hall
Journal:  J Genet Couns       Date:  2014-05-06       Impact factor: 2.537

Review 10.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.